More NewsRead More
SCYNEXIS Names Marco Taglietti, M.D., Chief Executive Officer
February 06, 2015
SCYNEXIS, Inc. Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections
January 09, 2015
SCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
December 03, 2014
SCYNEXIS, Inc. Reports Third Quarter 2014 Financial Results
November 13, 2014
SCYNEXIS, Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical for the Development and Commercialization of SCY-635 for Viral Diseases
November 03, 2014
SCYNEXIS, Inc. Reports Second Quarter 2014 Financial Results
August 13, 2014
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here